Qing Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Qing Sun has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Hongtao Liu
Department of Pathology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute, Shandong Institute of Nephrology, Jinan, Shandong Province, China
2 shared publicationsRuixue Tang
Department of Pathology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute, Shandong Institute of Nephrology, Jinan, Shandong Province, China
2 shared publicationsYuxia Cheng
Department of Pathology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute, Shandong Institute of Nephrology, Jinan, Shandong Province, China
2 shared publications- Bing Sun
Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington DC 20007, USA
1 shared publication Can Liu
Department of Pathology, Shandong Provincial Qianfoshan Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong Province, People’s Republic of China
1 shared publicationChao Song
Department of Pathology, Zibo Central Hospital, Zibo, Shandong Province, People’s Republic of China
1 shared publication
Latest Publications
- Open Access
- 27 May 2026
- Published by Wolters Kluwer Health in Journal of Cancer Research and Therapeutics
- Vol. 22 (2) , 334-342
Association between tissue origin classification and the clinical features and molecular phenotypes of nonsmall cell lung cancer
Background: Lung cancer is the most common malignancy in humans and the leading cause of cancer-related deaths worldwide. Nonsmall cell lung cancer (NSCLC), the primary histologic type, is categorized into lung adenocarcinoma (LUAD) and lung squamous cell carcinoma based on immunohistochemical thyroid transcription factor-1 and P40 status. LUAD is morphologically classified into five histological subtypes, based on physician experience, which can lead to confusion among pathologists and clinicians. Histological subtypes serve as crucial markers for lung cancer development and hold significant clinical value for cancer diagnosis, prognosis, and treatment response prediction. Aim: Identifying the various subtypes of NSCLC has become pivotal for enhancing diagnostic standards and patient prognosis. Methods and Results: In this study, we proposed a novel classification of NSCLC tissues into five subtypes (bronchial epithelial carcinoma, bronchiolar alveolar carcinoma, alveolar cell carcinoma, secretory adenocarcinoma, and mucinous adenocarcinoma) based on tissue origin. Furthermore, mRNA chip screening and next-generation sequencing revealed that these five subtypes exhibit distinct gene expression patterns and mutation signatures. Conclusion: This study proposes a novel NSCLC classification model designed to incorporate gene signatures into tissue origin-based histopathological subtypes, complementing the World Health Organization classification, and enhancing both diagnostic accuracy and clinical practicability.
- 27 May 2026
- Published by Wolters Kluwer Health in Journal of Cancer Research and Therapeutics
- Vol. 22 (2) , 334-342
Open AccessAssociation between tissue origin classification and the clinical features and molecular phenotypes of nonsmall cell lung cancer
Background: Lung cancer is the most common malignancy in humans and the leading cause of cancer-related deaths worldwide. Nonsmall cell lung cancer (NSCLC), the primary histologic type, is categorized into lung adenocarcinoma (LUAD) and lung squamous cell carcinoma based on immunohistochemical thyroid transcription factor-1 and P40 status. LUAD is morphologically classified into five histological subtypes, based on physician experience, which can lead to confusion among pathologists and clinicians. Histological subtypes serve as crucial markers for lung cancer development and hold significant clinical value for cancer diagnosis, prognosis, and treatment response prediction. Aim: Identifying the various subtypes of NSCLC has become pivotal for enhancing diagnostic standards and patient prognosis. Methods and Results: In this study, we proposed a novel classification of NSCLC tissues into five subtypes (bronchial epithelial carcinoma, bronchiolar alveolar carcinoma, alveolar cell carcinoma, secretory adenocarcinoma, and mucinous adenocarcinoma) based on tissue origin. Furthermore, mRNA chip screening and next-generation sequencing revealed that these five subtypes exhibit distinct gene expression patterns and mutation signatures. Conclusion: This study proposes a novel NSCLC classification model designed to incorporate gene signatures into tissue origin-based histopathological subtypes, complementing the World Health Organization classification, and enhancing both diagnostic accuracy and clinical practicability.
- Open Access
- 28 July 2023
- Published by Impact Journals, LLC in Aging
- Vol. 15 (14) , 7258-7277
The lipid peroxidation-derived DNA adduct γ-OHPdG as a diagnostic and prognostic biomarker in hepatocellular carcinoma
Purpose: Chronic inflammation and lipid peroxidation (LPO) are associated with the pathogenesis of hepatocellular carcinoma (HCC), and γ-hydroxy-1, N2-propanodeoxyguanosine (γ-OHPdG) is a promutagenic DNA adduct derived from LPO. This study aimed to examine the relationship between γ-OHPdG and the progression of liver carcinogenesis. Methods: Primary HCC specimens were obtained from 228 patients and cirrhosis specimens from 46 patients. The patients were followed up with after surgery via outpatient visits and telephone calls. The levels of γ-OHPdG were determined by immunohistochemical analysis in the carcinomatous tissues together with adjacent and cirrhosis tissues. Results: γ-OHPdG levels in the cancerous tissues were significantly higher compared to adjacent tissues (P < 0.001) and also higher than the ones from the tissues of cirrhosis patients. Along with tumor size, histological grade, MVI grade, T stage, the percentage of ki67-positive cells and HCC progression, γ-OHPdG levels in cancerous tissues showed a gradually increasing trend. Moreover, prognostic analysis showed that higher γ-OHPdG levels in cancerous tissues were strongly correlated with lower overall survival (P < 0.001), lower intrahepatic recurrence-free survival (P < 0.001) and lower distant metastasis-free survival (P < 0.05). There was a trend, although not statistically significant, of increased levels of γ-OHPdG in cirrhosis cases that advanced to HCC, whereas γ-OHPdG levels reversely correlated with the period of time observed for cirrhosis advanced to HCC. Conclusions: These results suggest that γ-OHPdG is a prognostic biomarker for predicting outcomes in HCC, and may serve as a prospective indicator for predicting HCC in cirrhosis patients.
- 28 July 2023
- Published by Impact Journals, LLC in Aging
- Vol. 15 (14) , 7258-7277
Open AccessThe lipid peroxidation-derived DNA adduct γ-OHPdG as a diagnostic and prognostic biomarker in hepatocellular carcinoma
Purpose: Chronic inflammation and lipid peroxidation (LPO) are associated with the pathogenesis of hepatocellular carcinoma (HCC), and γ-hydroxy-1, N2-propanodeoxyguanosine (γ-OHPdG) is a promutagenic DNA adduct derived from LPO. This study aimed to examine the relationship between γ-OHPdG and the progression of liver carcinogenesis. Methods: Primary HCC specimens were obtained from 228 patients and cirrhosis specimens from 46 patients. The patients were followed up with after surgery via outpatient visits and telephone calls. The levels of γ-OHPdG were determined by immunohistochemical analysis in the carcinomatous tissues together with adjacent and cirrhosis tissues. Results: γ-OHPdG levels in the cancerous tissues were significantly higher compared to adjacent tissues (P < 0.001) and also higher than the ones from the tissues of cirrhosis patients. Along with tumor size, histological grade, MVI grade, T stage, the percentage of ki67-positive cells and HCC progression, γ-OHPdG levels in cancerous tissues showed a gradually increasing trend. Moreover, prognostic analysis showed that higher γ-OHPdG levels in cancerous tissues were strongly correlated with lower overall survival (P < 0.001), lower intrahepatic recurrence-free survival (P < 0.001) and lower distant metastasis-free survival (P < 0.05). There was a trend, although not statistically significant, of increased levels of γ-OHPdG in cirrhosis cases that advanced to HCC, whereas γ-OHPdG levels reversely correlated with the period of time observed for cirrhosis advanced to HCC. Conclusions: These results suggest that γ-OHPdG is a prognostic biomarker for predicting outcomes in HCC, and may serve as a prospective indicator for predicting HCC in cirrhosis patients.
- Open Access
- 1 June 2020
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 12, 4261-4270
CFTR Functions as a Tumor Suppressor and Is Regulated by DNA Methylation in Colorectal Cancer
Purpose: Cystic fibrosis transmembrane conductance regulator (CFTR) was shown to be downregulated or silenced in carcinomas and acts as a candidate tumor suppressor gene. However, the function of CFTR gene in colorectal cancer (CRC) is still unclear. This aim of this study was to investigate the CFTR promoter methylation status and its impact on the expression and functional role of CFTR in CRC development. Patients and Methods: CFTR expression in CRC tissues and CRC cell lines was detected via quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry (IHC). The promoter methylation status of CFTR was measured using methylation-specific PCR (MSP). colony formation, transwell, and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays were used to evaluate the effect of CFTR overexpression in CRC cell lines. Results: qRT-PCR and IHC results indicated that CFTR expression was downregulated in the CRC tissues compared to the adjacent normal tissues. The promoter methylation status of CFTR was further analyzed in 70 CRC specimens. MSP validation showed methylation of CFTR promoter in 62.2% (45/70) of CRC tissues. The methylation of CFTR promoter was significantly associated with age (P=0.013) and lymph node metastasis (P=0.026) in CRC tissues. Results of transwell, MTT, and colony formation assays showed that CFTR overexpression inhibited the migration, invasion, and proliferation of CRC cells. Conclusion: CFTR expression was downregulated in CRC and promoter methylation may be responsible for this downregulation. Overexpression of CFTR may suppress CRC tumor growth by inhibiting the proliferation, migration, and invasion of CRC cells. CFTR promoter methylation was significantly correlated with lymph node metastasis; thus, CFTR may be a potential marker for lymph node metastasis of CRC.
- 1 June 2020
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 12, 4261-4270
Open AccessCFTR Functions as a Tumor Suppressor and Is Regulated by DNA Methylation in Colorectal Cancer
Purpose: Cystic fibrosis transmembrane conductance regulator (CFTR) was shown to be downregulated or silenced in carcinomas and acts as a candidate tumor suppressor gene. However, the function of CFTR gene in colorectal cancer (CRC) is still unclear. This aim of this study was to investigate the CFTR promoter methylation status and its impact on the expression and functional role of CFTR in CRC development. Patients and Methods: CFTR expression in CRC tissues and CRC cell lines was detected via quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry (IHC). The promoter methylation status of CFTR was measured using methylation-specific PCR (MSP). colony formation, transwell, and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays were used to evaluate the effect of CFTR overexpression in CRC cell lines. Results: qRT-PCR and IHC results indicated that CFTR expression was downregulated in the CRC tissues compared to the adjacent normal tissues. The promoter methylation status of CFTR was further analyzed in 70 CRC specimens. MSP validation showed methylation of CFTR promoter in 62.2% (45/70) of CRC tissues. The methylation of CFTR promoter was significantly associated with age (P=0.013) and lymph node metastasis (P=0.026) in CRC tissues. Results of transwell, MTT, and colony formation assays showed that CFTR overexpression inhibited the migration, invasion, and proliferation of CRC cells. Conclusion: CFTR expression was downregulated in CRC and promoter methylation may be responsible for this downregulation. Overexpression of CFTR may suppress CRC tumor growth by inhibiting the proliferation, migration, and invasion of CRC cells. CFTR promoter methylation was significantly correlated with lymph node metastasis; thus, CFTR may be a potential marker for lymph node metastasis of CRC.